Janux Therapeutics (JANX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.35
- Estimate
- -$0.30
- Surprise
- -16.8%
- Revenue (period 2026-06-30)
- $10.3M
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
Janux Therapeutics (JANX) reported a wider loss than forecast — adjusted EPS of -$0.35 against the -$0.30 estimate (a 16.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates JANX Sell at 4.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -16.8% surprise compares with a +13.7% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Pipeline: JANX007 and JANX008
- DATA_ISSUE: analyst_target_implausible (raw $33.14 vs price $10.92 — ratio 3.0×). Rejected, falling back to technical TP.
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.92
- Price target
- $18.25
- Stop
- $10.41
- Upside to target
- +67.1%
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
JANX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $695.7M
- P/E (fwd)
- -4.5
- 52-week range
- $11.15–$35.34
- Off 52-week high
- 69.1%
- RSI (14)
- 26
- Volume vs avg
- 0.76×
- Score today
- 4.0/10